4 completed, 1 enrolling by invitation. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 4, Enrolling by invitation 1 |
| Phase 2 | 1 | Completed 1 |
Follow OSA: new trials by email Literature Review of OSA trials Research Report on OSA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight Orforglipron, Placebo - OSA, Overweight or Obesity | Phase 3 | Completed | Eli Lilly and Company | 712 | 2024-10-22 | 2026-09-14 |
| Continuation Protocol for Obstructive Sleep Apnea (OSA) Aroxybutynin and Atomoxetine - OSA | Phase 3 | Enrolling by invitation | Apnimed | 1280 | 2024-07-03 | 2025-05-13 |
| Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study) AD109, Placebo - OSA | Phase 3 | Completed | Apnimed | 646 | 2023-09-16 | 2026-09-11 |
| Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo) AD109, Placebo - OSA | Phase 3 | Completed | Apnimed | 660 | 2023-08-28 | 2025-11-21 |
| Validation of the AVAPS AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD) Patients AVAPS-AE, Usual care - COPD, OSA | Phase 2 / Phase 3 | Completed | Patrick Murphy | 10 | 2012-05-01 | 2016-08-18 |
Sleep Apnea, Obstructive (3) · Obesity (1) · Overweight (1) · Pulmonary Disease, Chronic Obstructive (1) · Respiratory Insufficiency (1)
Respiration Disorders (4) · Respiratory Tract Diseases (4) · Apnea (3) · Dyssomnias (3) · Nervous System Diseases (3) · Sleep Apnea Syndromes (3) · Sleep Disorders, Intrinsic (3) · Sleep Wake Disorders (3) · Pathological Conditions, Signs and Symptoms (2) · Body Weight (1) · Chronic Disease (1) · Disease Attributes (1) · Lung Diseases (1) · Lung Diseases, Obstructive (1) · Nutrition Disorders (1)
Atomoxetine Hydrochloride (1) · orforglipron (1)
Apnimed (3) · Eli Lilly and Company (1) · Patrick Murphy (1)
United States (4) · Canada (2) · Argentina (1) · Brazil (1) · China (1) · Czechia (1) · Germany (1) · Japan (1) · Mexico (1) · Taiwan (1) · United Kingdom (1)
Nicholas Hart (1) · Ron Farkas, MD (1)